FDA 21 CFR 211.165 – Pharma GMP

Don’t Submit Certificates of Analysis Without QA Verification

digi — Thu, 16 Oct 2025 10:13:35 +0000

Don’t Submit Certificates of Analysis Without QA Verification Don’t Release Certificates of Analysis Without QA Review and Approval Remember: Always route CoAs through QA for verification — skipping this step may result in incorrect batch release and GMP violations. Why This Matters in GMP The Certificate of Analysis (CoA) is an official document that confirms...

Review Out of Trend (OOT) Results Periodically to Detect Emerging GMP Issues

digi — Sun, 05 Oct 2025 10:55:59 +0000

Review Out of Trend (OOT) Results Periodically to Detect Emerging GMP Issues Do Regularly Review Out of Trend (OOT) Results for Early GMP Warnings Remember: Always monitor OOT data trends — they help identify subtle issues before they escalate into OOS events or batch failures. Why This Matters in GMP Out of Trend (OOT) results...

Validate Analytical Methods Thoroughly Before Routine GMP Use

digi — Tue, 16 Sep 2025 13:10:24 +0000

Validate Analytical Methods Thoroughly Before Routine GMP Use Validate Analytical Methods Before Routine GMP Testing Begins Remember: Never use an analytical method in GMP testing without full validation — only validated methods guarantee data reliability and regulatory acceptance. Why This Matters in GMP Analytical methods are used in quality control laboratories to test the identity,...

Review Microbiological Test Results Promptly to Ensure Timely GMP Decisions

digi — Mon, 15 Sep 2025 00:49:54 +0000

Review Microbiological Test Results Promptly to Ensure Timely GMP Decisions Review Microbiological Results Without Delay to Safeguard GMP Decisions Remember: Always review microbiological test results promptly — delays can hinder product release, obscure trends, and increase compliance risks. Why This Matters in GMP Microbiological testing includes critical assessments like environmental monitoring (EM), bioburden, endotoxin, and...